{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:46Z","timestamp":1772166466259,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31802184"],"award-info":[{"award-number":["31802184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672048"],"award-info":[{"award-number":["81672048"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31572240"],"award-info":[{"award-number":["31572240"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31872959"],"award-info":[{"award-number":["31872959"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>New therapeutic drugs are urgently needed against visceral leishmaniasis because current drugs, such as pentavalent antimonials and miltefosine, produce severe side effects and development of resistance. Whether cyclosporine A (CsA) and its derivatives can be used as therapeutic drugs for visceral leishmaniasis has been controversial for many years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we evaluated the efficacy of CsA and its derivative, dihydrocyclosporin A (DHCsA-d), against promastigotes and intracellular amastigotes of\n                      <jats:italic>Leishmania donovani<\/jats:italic>\n                      . Sodium stibogluconate (SSG) was used as a positive control.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our results showed that DHCsA-d was able to inhibit the proliferation of\n                      <jats:italic>L. donovani<\/jats:italic>\n                      promastigotes (IC\n                      <jats:sub>50<\/jats:sub>\n                      : 21.24\u00a0\u03bcM and 12.14\u00a0\u03bcM at 24\u00a0h and 48\u00a0h, respectively) and intracellular amastigotes (IC\n                      <jats:sub>50<\/jats:sub>\n                      : 5.23\u00a0\u03bcM and 4.84\u00a0\u03bcM at 24 and 48\u00a0h, respectively)\n                      <jats:italic>in vitro<\/jats:italic>\n                      , but CsA treatment increased the number of amastigotes in host cells. Both DHCsA-d and CsA caused several alterations in the morphology and ultrastructure of\n                      <jats:italic>L. donovani<\/jats:italic>\n                      , especially in the mitochondria. However, DHCsA-d showed high cytotoxicity towards cells of the mouse macrophage cell line RAW264.7, with CC50 values of 7.98\u00a0\u03bcM (24\u00a0h) and 6.65\u00a0\u03bcM (48\u00a0h). Moreover, DHCsA-d could increase IL-12, TNF-\u03b1 and IFN-\u03b3 production and decrease the levels of IL-10, IL-4, NO and H\n                      <jats:sub>2<\/jats:sub>\n                      O\n                      <jats:sub>2<\/jats:sub>\n                      in infected macrophages. On the contrary, CsA decreased IL-12, TNF-\u03b1, and IFN-\u03b3 production and increased the levels of IL-10, IL-4, NO and H\n                      <jats:sub>2<\/jats:sub>\n                      O\n                      <jats:sub>2<\/jats:sub>\n                      in infected macrophages. The expression of\n                      <jats:italic>L. donovani<\/jats:italic>\n                      cyclophilin A (\n                      <jats:italic>Ld<\/jats:italic>\n                      CyPA) in promastigotes and intracellular amastigotes and the expression of cyclophilin A (CyPA) in RAW 264.7 cells were found to be significantly downregulated in the CsA-treated group compared to those in the untreated group. However, no significant changes in\n                      <jats:italic>Ld<\/jats:italic>\n                      CyPA and CyPA levels were found after DHCsA-d or SSG treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings initially resolved the dispute regarding the efficacy of CsA and DHCsA-d for visceral leishmaniasis treatment. CsA showed no significant inhibitory effect on intracellular amastigotes. DHCsA-d significantly inhibited promastigotes and intracellular amastigotes, but it was highly cytotoxic. Therefore, CsA and DHCsA-d are not recommended as antileishmanial drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-020-3958-x","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T09:03:43Z","timestamp":1582275823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of in vitro antileishmanial efficacy of cyclosporin A and its non-immunosuppressive derivative, dihydrocyclosporin A"],"prefix":"10.1186","volume":"13","author":[{"given":"Zhi-Wan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Lei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"3958_CR1","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7:e35671.","journal-title":"PLoS ONE"},{"key":"3958_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1128\/CMR.00080-14","volume":"28","author":"ZR Lun","year":"2015","unstructured":"Lun ZR, Wu MS, Chen YF, Wang JY, Zhou XN, Liao LF, et al. Visceral leishmaniasis in China: an endemic disease under control. Clin Microbiol Rev. 2015;28:987\u20131004.","journal-title":"Clin Microbiol Rev"},{"key":"3958_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1473-3099(02)00347-X","volume":"2","author":"PJ Guerin","year":"2002","unstructured":"Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis and treatment and a proposed research and development agenda. Lancet Infect Dis. 2002;2:494\u2013501.","journal-title":"Lancet Infect Dis"},{"key":"3958_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.intimp.2018.09.026","volume":"64","author":"K Chauhan","year":"2018","unstructured":"Chauhan K, Kaur G, Kaur S. Activity of rutin, a potent flavonoid against SSG-sensitive and -resistant Leishmania donovani parasites in experimental leishmaniasis. Int Immunopharmacol. 2018;64:372\u201385.","journal-title":"Int Immunopharmacol"},{"key":"3958_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/0306-3623(95)02148-5","volume":"27","author":"A Bell","year":"1996","unstructured":"Bell A, Roberts HC, Chappell LH. The antiparasite effects of cyclosporin A: possible drug targets and clinical applications. Gen Pharmacol. 1996;27:963\u201371.","journal-title":"Gen Pharmacol"},{"issue":"Suppl.","key":"3958_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1017\/S0031182000075338","volume":"105","author":"LH Chappell","year":"1992","unstructured":"Chappell LH, Wastling JM. Cyclosporin A: antiparasite drug, modulator of the host-parasite relationship and immunosuppressant. Parasitology. 1992;105(Suppl.):25\u201340.","journal-title":"Parasitology"},{"key":"3958_CR7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.137.2.702","volume":"137","author":"W Solbach","year":"1986","unstructured":"Solbach W, Forberg K, Kammerer E, Bogdan C, Rollinghoff M. Suppressive effect of cyclosporin A on the development of Leishmania tropica-induced lesions in genetically susceptible BALB\/c mice. J Immunol. 1986;137:702\u20137.","journal-title":"J Immunol"},{"key":"3958_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1128\/IAI.54.3.909-912.1986","volume":"54","author":"W Solbach","year":"1986","unstructured":"Solbach W, Forberg K, Rollinghoff M. Effect of T-lymphocyte suppression on the parasite burden in Leishmania major-infected, genetically susceptible BALB\/c mice. Infect Immun. 1986;54:909\u201312.","journal-title":"Infect Immun"},{"key":"3958_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1046\/j.1365-2958.1997.3401716.x","volume":"24","author":"A Hoerauf","year":"1997","unstructured":"Hoerauf A, Rascher C, Bang R, Pahl A, Solbach W, Brune K, et al. Host-cell cyclophilin is important for the intracellular replication of Leishmania major. Mol Microbiol. 1997;24:421\u20139.","journal-title":"Mol Microbiol"},{"key":"3958_CR10","first-page":"301","volume":"19","author":"A Eldaw","year":"1989","unstructured":"Eldaw A, Sequeira RP, Eldirdiri AB. A preliminary observation on in vitro inhibitory effect of cyclosporin-A upon growth of Leishmania tropica promastigotes. J Egypt Soc Parasitol. 1989;19:301\u20135.","journal-title":"J Egypt Soc Parasitol"},{"key":"3958_CR11","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1371\/journal.pntd.0000729","volume":"4","author":"WL Yau","year":"2010","unstructured":"Yau WL, Blisnick T, Taly JF, Helmer-Citterich M, Schiene-Fischer C, Leclercq O, et al. Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability. PLoS Negl Trop Dis. 2010;4:e729.","journal-title":"PLoS Negl Trop Dis"},{"key":"3958_CR12","first-page":"906","volume":"33","author":"M Merelli","year":"2015","unstructured":"Merelli M, Quartuccio L, Bassetti M, Pecori D, Gandolfo S, Avellini C, et al. Efficacy of intravenous cyclosporine in a case of cytophagic histiocytic panniculitis complicated by haemophagocytic syndrome after visceral leishmania infection. Clin Exp Rheumatol. 2015;33:906\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"3958_CR13","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1128\/IAI.58.9.3151-3153.1990","volume":"58","author":"LE Adinolfi","year":"1990","unstructured":"Adinolfi LE, Bonventre PF. Cyclosporin A treatment converts Leishmania donovani-infected C57BL\/10 (curing) mice to a noncuring phenotype. Infect Immun. 1990;58:3151\u20133.","journal-title":"Infect Immun"},{"key":"3958_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2307\/3283056","volume":"75","author":"M Olivier","year":"1989","unstructured":"Olivier M, Proulx C, Tanner CE. Importance of lymphokines in the control of multiplication and dispersion of Leishmania donovani within liver macrophages of resistant and susceptible mice. J Parasitol. 1989;75:720\u20137.","journal-title":"J Parasitol"},{"key":"3958_CR15","first-page":"32","volume":"40","author":"M Olivier","year":"1989","unstructured":"Olivier M, Tanner CE. The effect of cyclosporin A in murine visceral leishmaniasis. Trop Med Parasitol. 1989;40:32\u20138.","journal-title":"Trop Med Parasitol"},{"key":"3958_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1017\/S0031182096008190","volume":"114","author":"HC Roberts","year":"1997","unstructured":"Roberts HC, Sternberg JM, Chappell LH. Characterization of calcineurin from Hymenolepis microstoma and H. diminuta and its interaction with cyclosporin A. Parasitology. 1997;114:279\u201383.","journal-title":"Parasitology"},{"key":"3958_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.117.310661","volume":"35","author":"C Xue","year":"2018","unstructured":"Xue C, Sowden MP, Berk BC. Extracellular and intracellular cyclophilin A, native and post-translationally modified, show diverse and specific pathological roles in diseases. Arterioscler Thromb Vasc Biol. 2018;35:986\u201393.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3958_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/ng2053","volume":"39","author":"CS Peacock","year":"2007","unstructured":"Peacock CS, Seeger K, Harris D, Murphy L, Ruiz JC, Quail MA, et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet. 2007;39:839\u201347.","journal-title":"Nat Genet"},{"key":"3958_CR19","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1101\/gr.122945.111","volume":"21","author":"MB Rogers","year":"2011","unstructured":"Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, Depledge DP, et al. Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res. 2011;21:2129\u201342.","journal-title":"Genome Res"},{"key":"3958_CR20","doi-asserted-by":"publisher","first-page":"E132","DOI":"10.3390\/biom8040132","volume":"8","author":"AE Perrone","year":"2018","unstructured":"Perrone AE, Milduberger N, Fuchs AG, Bustos PL, Bua J. A functional analysis of the cyclophilin repertoire in the protozoan parasite Trypanosoma cruzi. Biomolecules. 2018;8:E132.","journal-title":"Biomolecules"},{"key":"3958_CR21","first-page":"68","volume":"18","author":"GP Meier","year":"1990","unstructured":"Meier GP, Park SB, Yee GC, Gmur DJ. Isolation and identification of a novel human metabolite of cyclosporin A: dihydro-CsA M17. Drug Metab Dispos. 1990;18:68\u201371.","journal-title":"Drug Metab Dispos"},{"key":"3958_CR22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1128\/AAC.31.10.1567","volume":"31","author":"LH Chappell","year":"1987","unstructured":"Chappell LH, Thomson AW, Barker GC, Smith SW. Dosage, timing, and route of administration of cyclosporin A and nonimmunosuppressive derivatives of dihydrocyclosporin A and cyclosporin C against Schistosoma mansoni in vivo and in vitro. Antimicrob Agents Chemother. 1987;31:1567\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"3958_CR23","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1111\/febs.14923","volume":"286","author":"J Veronica","year":"2019","unstructured":"Veronica J, Chandrasekaran S, Dayakar A, Devender M, Prajapati VK, Sundar S, et al. Iron superoxide dismutase contributes to miltefosine resistance in Leishmania donovani. FEBS J. 2019;286:3488\u2013503.","journal-title":"FEBS J"},{"key":"3958_CR24","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1128\/AAC.00548-09","volume":"53","author":"M Vermeersch","year":"2009","unstructured":"Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, Maes L. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother. 2009;53:3855\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"3958_CR25","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1086\/587899","volume":"46","author":"R ter Horst","year":"2008","unstructured":"ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis. 2008;46:1702\u20139.","journal-title":"Clin Infect Dis"},{"key":"3958_CR26","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/jac\/dky229","volume":"73","author":"S Teixeira de Macedo Silva","year":"2018","unstructured":"Teixeira de Macedo Silva S, Visbal G, Lima Prado Godinho J, Urbina JA, de Souza W, Cola Fernandes Rodrigues J. In vitro antileishmanial activity of ravuconazole, a triazole antifungal drug, as a potential treatment for leishmaniasis. J Antimicrob Chemother. 2018;73:2360\u201373.","journal-title":"J Antimicrob Chemother"},{"key":"3958_CR27","doi-asserted-by":"publisher","first-page":"e83247","DOI":"10.1371\/journal.pone.0083247","volume":"8","author":"ST de Macedo-Silva","year":"2013","unstructured":"de Macedo-Silva ST, Urbina JA, de Souza W, Rodrigues JC. In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis. PLoS ONE. 2013;8:e83247.","journal-title":"PLoS ONE"},{"key":"3958_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4269\/ajtmh.2007.76.669","volume":"76","author":"RM Mukbel","year":"2007","unstructured":"Mukbel RM, Patten C Jr, Gibson K, Ghosh M, Petersen C, Jones DE. Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide. Am J Trop Med Hyg. 2007;76:669\u201375.","journal-title":"Am J Trop Med Hyg"},{"key":"3958_CR29","doi-asserted-by":"publisher","first-page":"e2914","DOI":"10.1371\/journal.pntd.0002914","volume":"8","author":"RJ Faleiro","year":"2014","unstructured":"Faleiro RJ, Kumar R, Hafner LM, Engwerda CR. Immune regulation during chronic visceral leishmaniasis. PLoS Negl Trop Dis. 2014;8:e2914.","journal-title":"PLoS Negl Trop Dis"},{"key":"3958_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1365-2567.1997.00193.x","volume":"90","author":"R Hernandez-Pando","year":"1997","unstructured":"Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Madrid-Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. Immunology. 1997;90:607\u201317.","journal-title":"Immunology"},{"key":"3958_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.0105-2896.2004.00211.x","volume":"202","author":"WT Watford","year":"2004","unstructured":"Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O\u2019Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139\u201356.","journal-title":"Immunol Rev"},{"key":"3958_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/intimm\/dxx075","volume":"30","author":"M Rossi","year":"2018","unstructured":"Rossi M, Fasel N. How to master the host immune system? Leishmania parasites have the solutions! Int Immunol. 2018;30:103\u201311.","journal-title":"Int Immunol"},{"key":"3958_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jtcme.2017.06.006","volume":"8","author":"R Kaur","year":"2018","unstructured":"Kaur R, Kaur S. Evaluation of in vitro and in vivo antileishmanial potential of bergenin rich Bergenia ligulata (Wall.) Engl. root extract against visceral leishmaniasis in inbred BALB\/c mice through immunomodulation. J Tradit Complement Med. 2018;8:251\u201360.","journal-title":"J Tradit Complement Med"},{"key":"3958_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1476-9255-7-8","volume":"7","author":"NJ Lapara 3rd","year":"2010","unstructured":"Lapara NJ 3rd, Kelly BL. Suppression of LPS-induced inflammatory responses in macrophages infected with Leishmania. J Inflamm. 2010;7:8.","journal-title":"J Inflamm"},{"key":"3958_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1385\/IR:26:1-3:095","volume":"26","author":"KE Iles","year":"2002","unstructured":"Iles KE, Forman HJ. Macrophage signaling and respiratory burst. Immunol Res. 2002;26:95\u2013105.","journal-title":"Immunol Res"},{"key":"3958_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nrmicro1004","volume":"2","author":"FC Fang","year":"2004","unstructured":"Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol. 2004;2:820\u201332.","journal-title":"Nat Rev Microbiol"},{"key":"3958_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/cmi.2014.89","volume":"12","author":"A Panday","year":"2015","unstructured":"Panday A, Sahoo MK, Osorio D, Batra S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol. 2015;12:5\u201323.","journal-title":"Cell Mol Immunol"},{"key":"3958_CR38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.lfs.2003.10.042","volume":"75","author":"F Aktan","year":"2004","unstructured":"Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75:639\u201353.","journal-title":"Life Sci"},{"key":"3958_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40409-016-0055-x","volume":"22","author":"AV Pereira","year":"2016","unstructured":"Pereira AV, de Barros G, Pinto EG, Tempone AG, Orsi Rde O, Dos Santos LD, et al. Melittin induces in vitro death of Leishmania (Leishmania) infantum by triggering the cellular innate immune response. J Venom Anim Toxins Incl Trop Dis. 2016;22:1.","journal-title":"J Venom Anim Toxins Incl Trop Dis"},{"key":"3958_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00436-002-0743-z","volume":"89","author":"U Meissner","year":"2003","unstructured":"Meissner U, Juttner S, Rollinghoff M, Gessner A. Cyclosporin A-mediated killing of Leishmania major by macrophages is independent of reactive nitrogen and endogenous TNF-alpha and is not inhibited by IL-10 and 13. Parasitol Res. 2003;89:221\u20137.","journal-title":"Parasitol Res"},{"key":"3958_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0006-2952(94)90279-8","volume":"48","author":"A Bell","year":"1994","unstructured":"Bell A, Wernli B, Franklin RM. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin. Biochem Pharmacol. 1994;48:495\u2013503.","journal-title":"Biochem Pharmacol"},{"key":"3958_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0378-1097(01)00193-8","volume":"200","author":"J Bua","year":"2001","unstructured":"Bua J, Aslund L, Pereyra N, Garcia GA, Bontempi EJ, Ruiz AM. Characterisation of a cyclophilin isoform in Trypanosoma cruzi. FEMS Microbiol Lett. 2001;200:43\u20137.","journal-title":"FEMS Microbiol Lett"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-3958-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13071-020-3958-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-3958-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T06:00:21Z","timestamp":1695794421000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-3958-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3958"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-3958-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737418035.793580949","asserted-by":"object"}]},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"4 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Sichuan University Medical Ethics Committee (Approval Number: K2018056). All animal experimental procedures were performed according to the regulations laid down by the Administration of Affairs Concerning Experimental Animals approved by the State Council of People\u2019s Republic of China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}